PDS Biotechnology Corporation PDSB

PDS Biotech announced the publication in JAMA Oncology of Versatile-002 results evaluating PDS0101 (HPV16-targeted immunotherapy) with pembrolizumab in HPV16-positive recurrent/metastatic head and neck cancer. In the ICI-naïve mITT cohort (n=53) 62.3% had CPS 1-19 and 37.7% had CPS ≥20; median overall survival in CPS≥1 population reached 39.3 months (95% CI: 23.9 to NE), versus 17.9 months for published SOC pembrolizumab regimens. Objective response rate for CPS≥1 was 36% (investigator review) or 34% (central review), higher than the 19% reported for standard pembrolizumab alone. Safety was favorable with 13.8% Grade ≥3 TRAEs, one Grade 4 event at year one, and noGrade 5. The trial was open-label and nonrandomized across 26 centers; 88 enrolled, 87 treated. PDS discusses pursuing partnerships for PDS0101 Phase 3 and continued development of PDS0301 in mCRC. Nonrandomized Phase 2 results showing a substantial OS advantage and higher ORR could accelerate partnerships, Phase 3 development, and investor interest, altering the company's near-term trajectory.

PDS Biotechnology Corporation has achieved a significant milestone in the VERSATILE-002 trial for head and neck cancer, demonstrating extended survival in patients with low PD-L1 expression (CPS 1–19). This breakthrough suggests the potential to eliminate the need for chemotherapy in this patient population, marking a notable advancement in cancer treatment. The trial results indicate a major strategic advancement that could significantly alter treatment protocols and investor sentiment.

PDS Biotechnology (PDSB) stock fair value lowers after analysts cut ratings amid financing scrutiny. Analyst cuts and financing scrutiny reduce PDSB fair value estimates and pressure market sentiment.

PDS Biotechnology surged in September as a billionaire's backing drove outperformance versus Moderna, Iovance and Sellas. Billionaire-fueled rally signals stronger investor interest and improved market positioning for PDSB.

PDS Biotech announces initial closing of up to $22.3 million PIPE financing and appoints Dr. Patrick Soon-Shiong to its board of directors. PIPE financing supplies critical capital for operations while Soon-Shiong board appointment adds high-level biotech expertise and credibility.

PDS Biotechnology Corporation secures up to $22.55 million financing led by Dr. Patrick Soon-Shiong, founder of NantWorks. Major capital infusion directly bolsters PDSB cash reserves and development runway.

PDS Biotechnology refocuses on PDS0301 for metastatic colorectal cancer treatment and seeks partnerships for PDS0101. Pipeline prioritization and partnership strategy represent major moves that can significantly alter company trajectory.

PDS Biotechnology Corporation (PDSB) highlighted strategic advancements in its Q1 2026 earnings call. Strategic advancements detailed in Q1 2026 earnings call represent major moves likely to alter PDSB's trajectory and investor sentiment.

PDS Biotechnology Corporation released the complete transcript of its Q1 2026 earnings call, detailing financial results, operational updates, and strategic outlook. Q1 2026 earnings call transcript reveals financial performance, pipeline progress, and guidance that could significantly sway investor sentiment and stock trajectory.

PDS Biotechnology Corporation (PDSB) released Q1 earnings call highlights covering financial results, clinical trial progress, and strategic updates. Q1 earnings highlights address financial performance and pipeline developments with moderately noticeable effects on investor sentiment and stock trajectory.

PDS Biotechnology Corporation (PDSB) released Q1 2026 earnings call summary highlighting financial results, clinical pipeline progress, and strategic updates. Q1 2026 earnings call summary details financial performance and clinical developments with moderate influence on PDSB's trajectory and investor sentiment.

PDS Biotechnology reported first-quarter 2026 financial results and provided updates on clinical programs and corporate developments. Quarterly financial results combined with clinical program updates offer moderate insights into cash runway and pipeline progress without indicated major breakthroughs.

PDS Biotechnology announces publication of positive interim Phase 2 clinical trial data for PDS01ADC from Stage 1 of NCI-led metastatic colorectal cancer (mCRC) trial. Positive interim Phase 2 data from NCI-led mCRC trial represents a major clinical milestone that could significantly enhance PDSB's pipeline value and investor sentiment.

PDS Biotechnology Corporation released Q4 2025 earnings call summary covering financial results, pipeline updates, and strategic outlook. Q4 earnings summary details financial performance and pipeline progress, significantly impacting investor sentiment and company trajectory.

PDS Biotechnology Corporation reported full-year 2025 financial results and provided updates on the PDS0101 Phase 3 program and PDS01ADC clinical advancement. Full-year financial results combined with Phase 3 PDS0101 updates and PDS01ADC clinical progress represent major pipeline advancements impacting future performance.

PDS Biotechnology Corp (PDSB) Q4 2025 earnings call highlights financial discipline amid challenges, with key updates on operations and outlook. Earnings call highlights reveal financial discipline amid challenges, moderately influencing financial performance and investor sentiment.

PDS Biotechnology adopts amended protocol for Phase 3 VERSATILE-003 trial, incorporating Progression Free Survival (PFS) as primary endpoint for interim analysis to support potential accelerated FDA approval. Amending Phase 3 trial to PFS primary endpoint accelerates path to potential approval, significantly enhancing PDSB's clinical and market prospects.

PDS Biotechnology Corporation announced preliminary results from a Phase 2 study of its IL-12 tumor-targeted immunocytokine, PDS01ADC, for patients with 3rd line metastatic castration-resistant prostate cancer, conducted by the National Cancer Institute. The study aims to evaluate the safety and efficacy of PDS01ADC, which targets tumors while minimizing effects on healthy tissue. Initial findings indicate promising outcomes, potentially paving the way for further clinical development and regulatory approval. Promising preliminary results from the Phase 2 study could significantly influence PDSB's future market performance and investor sentiment.

PDS Biotechnology Corporation announced the issuance of a new U.S. patent that covers the technology underlying its lead product candidate, PDS0101. This patent is expected to enhance the company's intellectual property portfolio and support its ongoing clinical development efforts in immunotherapy for cancer treatment. The patent strengthens PDSB's position in the competitive landscape of cancer therapeutics and may facilitate future partnerships and funding opportunities. The new patent significantly enhances PDSB's competitive position and could lead to major strategic moves in product development and partnerships.

PDS Biotechnology Corporation announced that the FDA has aligned with its use of Progression Free Survival (PFS) as a primary endpoint in clinical trials. This alignment is expected to facilitate the development of PDSB's immunotherapy treatments, potentially accelerating the approval process and enhancing the company's strategic positioning in the oncology market. FDA alignment on PFS as a primary endpoint is a significant regulatory milestone that could enhance product development and market positioning.

PDS Biotechnology Corporation has announced the issuance of a new composition of matter patent for its lead product candidate, PDS0101, in Japan. This patent is expected to enhance the company's intellectual property portfolio and support its ongoing development efforts in immunotherapy for cancer treatment. The patent will provide PDSB with exclusive rights to the composition, potentially strengthening its market position and competitive edge in the biotechnology sector. The new patent is likely to significantly enhance PDSB's competitive position and support its strategic initiatives in the immunotherapy market.

PDS Biotechnology Corporation (PDSB) has been upgraded to a 'Buy' rating by analysts, reflecting positive sentiment regarding its pipeline and potential market performance. The upgrade is attributed to promising developments in its lead product candidate, which targets cancer treatment. Analysts believe that recent clinical trial results and strategic partnerships position the company favorably for future growth. This upgrade is expected to enhance investor confidence and could lead to increased market interest in PDSB shares. The upgrade indicates significant potential for future growth driven by promising clinical developments and strategic positioning.

PDS Biotechnology Corporation has announced the scheduling of a Type C meeting with the U.S. Food and Drug Administration (FDA). This meeting is a critical step in the regulatory process for the company's product development, allowing for discussions on the development plan and potential pathways for approval. The Type C meeting with the FDA is a significant regulatory milestone that could influence the company's product approval process and market positioning.

PDS Biotechnology Corporation reported its Q3 2025 earnings, highlighting strategic advances in its product pipeline and ongoing clinical trials. The company emphasized its commitment to innovation and expanding its market presence, showcasing positive developments in its lead immunotherapy candidates. Financial results indicated growth, with increased revenue and reduced losses compared to previous quarters. Management expressed optimism about upcoming milestones and potential partnerships that could enhance the company's competitive positioning in the biotechnology sector. Significant strategic advances and positive financial results are likely to impact future performance and investor sentiment.

PDS Biotechnology Corporation reported its Q3 earnings, highlighting key financial metrics and operational updates. The company continues to advance its clinical programs and is focused on expanding its pipeline. Financial results indicate progress in revenue generation and investment in research and development. The management provided insights into future strategies and market positioning, emphasizing the potential for growth in the biotechnology sector. The earnings report reflects moderate progress in financial performance and operational strategy, which may influence investor sentiment and market positioning.

PDS Biotechnology Corporation reported its financial results for the third quarter of 2025, highlighting advancements in its clinical programs. The company continues to focus on its innovative immunotherapy treatments, with updates on ongoing trials and collaborations aimed at enhancing its product pipeline. Financial metrics indicate a stable position, with investments directed towards research and development efforts. The outlook remains positive as PDSB aims to leverage its clinical data to attract potential partnerships and funding opportunities. Ongoing clinical programs and financial stability may moderately influence PDSB's market position and investor sentiment.

PDS Biotechnology Corporation announced a registered direct offering of up to $11.1 million. The offering is expected to enhance the company's financial position and support its ongoing development initiatives. The company plans to use the proceeds for general corporate purposes, including advancing its clinical programs. The offering may provide necessary funding for clinical programs, impacting financial performance and operational capabilities.

PDS Biotechnology Corporation announced promising translational data demonstrating strong immunological and clinical activity for its products PDS0101 and PDS01ADC at the SITC 2025 conference. The data highlights the potential effectiveness of these therapies in treating cancer, suggesting a positive outlook for their development and future clinical applications. The presentation of strong clinical data could significantly enhance the company's product positioning and investor sentiment.

PDS Biotechnology Corporation will present new clinical and translational data on its investigational cancer therapies, PDS0101 and PDS01ADC, at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting. This presentation aims to showcase advancements in the company's cancer treatment pipeline and its potential impact on patient outcomes. The presentation of new clinical data could significantly influence investor sentiment and the company's competitive positioning in the oncology market.

PDS Biotechnology Corporation announced plans to seek an expedited approval pathway for its investigational therapy PDS0101, aimed at treating HPV16-positive head and neck cancer. This initiative is part of the company's strategy to accelerate the development and availability of its treatment options for patients affected by this type of cancer. Seeking expedited approval for a cancer treatment could significantly enhance the company's market position and investor sentiment.